Sibylle Haid

Sibylle Haid

Auto-generated profile, based on publicly available information

Sibylle Haid

Institute for Experimental Virology, Centre for Experimental and Clinical Infection Research, a Joint Venture between the Helmholtz Centre for Infection Research and the Hannover Medical School, TWINCORE

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JSJonas Schuhenn
Jonas Schuhenn
TMToni Luise Meister
Toni Luise Meister
Daniel TodtDaniel Todt
Daniel Todt
TBThilo Bracht
Thilo Bracht
KSKarin Schork
Karin Schork
SPStephanie Pfaender
Stephanie Pfaender
Significance: Type I interferons (IFN-I) exhibit various biological effects during viral infections, and they have been successfully used for clinical treatment of viral diseases. Humans express 12 IFNα subtypes, which strongly differ in their antiviral responses against different viruses. Here we analyzed the antiviral activity of all human IFNα subtypes against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to identify the underlying immune signatures and explore their therapeutic potential. Our data provide a systemic pattern of antiviral host effector responses mediated by high antiviral IFN-I, which could help to identify key cellular effectors targeted in novel therapeutic approaches against SARS-CoV-2 infection.

8 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SSSvenja M. Sake
Svenja M. Sake
XZXiaoyu Zhang
Xiaoyu Zhang
MRManoj Kumar Rajak
Manoj Kumar Rajak
MUMelanie Urbanek-Quaing
Melanie Urbanek-Quaing
ACArnaud Carpentier
Arnaud Carpentier
TPThomas Pietschmann
Thomas Pietschmann
Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infection in infants, older adults and the immunocompromised. Effective directly acting antivirals are not yet available for clinical use. To address this, we screen the ReFRAME drug-repurposing library consisting of 12,000 small molecules against RSV. We identify 21 primary candidates including RSV F and N protein inhibitors, five HSP90 and four IMPDH inhibitors. We select lonafarnib, a licensed farnesyltransferase inhibitor, and phase III candidate for hepatitis delta virus (HDV) therapy, for further follow-up. Dose-response analyses and plaque assays confirm the antiviral activity (IC50: 10-118 nM). Passaging of RSV with lonafarnib selects for phenotypic resistance and fixation of mutations in the RSV fusion protein (T335I and T400A). Lentiviral pseudotypes programmed with variant RSV fusion proteins confirm that lonafarnib inhibits RSV cell entry and that these mutations confer lonafarnib resistance. Surface plasmon resonance reveals RSV fusion protein binding of lonafarnib and co-crystallography identifies the lonafarnib binding site within RSV F. Oral administration of lonafarnib dose-dependently reduces RSV virus load in a murine infection model using female mice. Collectively, this work provides an overview of RSV drug repurposing candidates and establishes lonafarnib as a bona fide fusion protein inhibitor.

2 April 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
WJWendy K. Jo
Wendy K. Jo
ASAlina Schadenhofer
Alina Schadenhofer
AHAndre Habierski
Andre Habierski
FKFranziska K. Kaiser
Franziska K. Kaiser
GSGiulietta Saletti
Giulietta Saletti
MLMartin Ludlow
Martin Ludlow
Significance: Respiratory syncytial virus (RSV) remains a major cause of severe respiratory disease worldwide in children, older individuals, and immunosuppressed patients. An increasing understanding of this disease burden together with the absence of an effective vaccine and limited therapeutic options has resulted in many new preclinical and clinical studies into novel vaccines, antibodies, and antivirals. This requires complementary expansion of the RSV molecular toolkit to encompass reverse genetics systems based on contemporary strains. We show that full-length cDNA clones of recent strains are most stable when a bacterial artificial chromosome is used as the vector backbone. This enabled recombinant viruses encoding antibody escape mutations to be generated and assessed with respect to antibody escape and capacity to induce cell-to-cell fusion.

1 May 2020 in Antiviral Research
Verified
Journal Article
Open access
SBSebastian Blockus
Sebastian Blockus
SSSvenja M. Sake
Svenja M. Sake
MWMartin Wetzke
Martin Wetzke
CGChristina Grethe
Christina Grethe
TGTheresa Graalmann
Theresa Graalmann
TPThomas Pietschmann
Thomas Pietschmann
Acute lower respiratory tract infections (ALRI) caused by respiratory syncytial virus (RSV) are associated with a severe disease burden among infants and elderly patients. Treatment options are limited. While numerous drug candidates with different viral targets are under development, the utility of RSV entry inhibitors is challenged by a low resistance barrier and by single mutations causing cross-resistance against a wide spectrum of fusion inhibitor chemotypes. We developed a cell-based screening assay for discovery of compounds inhibiting infection with primary RSV isolates. Using this system, we identified labyrinthopeptin A1 and A2 (Laby A1/A2), lantibiotics isolated from Actinomadura namibiensis, as effective RSV cell entry inhibitors with IC50s of 0.39 μM and 4.97 μM, respectively, and with favourable therapeutic index (>200 and > 20, respectively). Both molecules were active against multiple RSV strains including primary isolates and their antiviral activity against RSV was confirmed in primary human airway cells ex vivo and a murine model in vivo. Laby A1/A2 were antiviral in prophylactic and therapeutic treatment regimens and displayed synergistic activity when applied in combination with each other. Mechanistic studies showed that Laby A1/A2 exert virolytic activity likely by binding to phosphatidylethanolamine moieties within the viral membrane and by disrupting virus particle membrane integrity. Probably due to its specific mode of action, Laby A1/A2 antiviral activity was not affected by common resistance mutations to known RSV entry inhibitors. Taken together, Laby A1/A2 represent promising candidates for development as RSV inhibitors. Moreover, the cell-based screening system with primary RSV isolates described here should be useful to identify further antiviral agents.

28 November 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PHPatrick A. Haack
Patrick A. Haack
KHKirsten Harmrolfs
Kirsten Harmrolfs
Chantal Denise BaderChantal Denise Bader
Chantal Denise Bader
RGRonald Garcia
Ronald Garcia
AGAntonia P. Gunesch
Antonia P. Gunesch
RMRolf Müller
Rolf Müller
During our search for novel myxobacterial natural products, we discovered the thiamyxins: thiazole‐ and thiazoline‐rich non‐ribosomal peptide‐polyketide hybrids with potent antiviral activity. We isolated four congeners of this unprecedented natural product family with the non‐cyclized thiamyxin D fused to a glycerol unit at the C‐terminus. Alongside their structure elucidation, we present a concise biosynthesis model based on biosynthetic gene cluster analysis and isotopically labelled precursor feeding. We report incorporation of a 2‐(hydroxymethyl)‐4‐methylpent‐3‐enoic acid moiety by a GCN5‐related N‐acetyltransferase‐like decarboxylase domain featuring polyketide synthase. The thiamyxins show potent inhibition of RNA viruses in cell culture models of corona, zika and dengue virus infection. Their potency up to a half maximal inhibitory concentration of 560 nM combined with milder cytotoxic effects on human cell lines indicate the potential for further development of the thiamyxins.

6 March 2024 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
SHSibylle Haid
Sibylle Haid
AMAlina Matthaei
Alina Matthaei
MWMelina Winkler
Melina Winkler
SSSvenja M. Sake
Svenja M. Sake
AGAntonia P. Gunesch
Antonia P. Gunesch
TPThomas Pietschmann
Thomas Pietschmann
Libraries composed of licensed drugs represent a vast repertoire of molecules modulating physiological processes in humans, providing unique opportunities for the discovery of host-targeting antivirals. We screened the Repurposing, Focused Rescue, and Accelerated Medchem (ReFRAME) repurposing library with approximately 12,000 molecules for broad-spectrum coronavirus antivirals and discovered 134 compounds inhibiting an alphacoronavirus and mapping to 58 molecular target categories. Dominant targets included the 5-hydroxytryptamine receptor, the dopamine receptor, and cyclin-dependent kinases. Gene knock-out of the drugs’ host targets including cathepsin B and L (CTSB/L; VBY-825), the aryl hydrocarbon receptor (AHR; Phortress), the farnesyl-diphosphate farnesyltransferase 1 (FDFT1; P-3622), and the kelch-like ECH-associated protein 1 (KEAP1; Omaveloxolone), significantly modulated HCoV-229E infection, providing evidence that these compounds inhibited the virus through acting on their respective host targets. Counter-screening of all 134 primary compound candidates with SARS-CoV-2 and validation in primary cells identified Phortress, an AHR activating ligand, P-3622-targeting FDFT1, and Omaveloxolone, which activates the NFE2-like bZIP transcription factor 2 (NFE2L2) by liberating it from its endogenous inhibitor KEAP1, as antiviral candidates for both an Alpha - and a Betacoronavirus . This study provides an overview of HCoV-229E repurposing candidates and reveals novel potentially druggable viral host dependency factors hijacked by diverse coronaviruses.